Navigating the complexities of cell and gene therapy requires a strategic approach to GMP compliance, regulatory submissions, and operational scale-up. Our extended services are designed specifically for biotech startups in transition—bridging the gap between innovation and compliance.

We provide:
✔ Regulatory strategy development to align with FDA and EMA requirements
✔ GMP implementation to support early-stage and clinical manufacturing
✔ Risk-based quality management to optimize compliance and scalability
✔ Operational readiness assessments for facility and process validation

With deep expertise in ATMPs, cell & gene therapy, and biotech manufacturing, we help emerging companies establish a strong regulatory foundation for long-term success.

In an increasingly complex regulatory landscape, our expertise ensures compliance with the highest industry standards. We specialize in risk assessments, regulatory evaluations, toxicology assessments, and quality assurance strategies tailored to pharmaceutical and life sciences industries. By integrating Good Manufacturing Practices (GMP), FDA, and ICH guidelines, we provide comprehensive risk-based approaches that strengthen regulatory submissions, support safe and effective product development, and safeguard patient safety.

Partner with us for data-driven risk assessments that safeguard compliance, enhance operational efficiency, and mitigate regulatory challenges.

Most GxP organisations manage their document register the same way: a spreadsheet, manually maintained, version-controlled by filename, and quietly non-compliant.

Our DocIDManager replaces spreadsheets with a purpose-built desktop application that generates audit-ready document IDs, enforces individual numbering schema, and maintains a tamper-evident audit trail with a cryptographic hash chain: every entry is traceable, every gap is visible, and no inspector can question the integrity. Deployable company wide with one annual license. No server. No cloud. No compliance debt.